Trial Profile
Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary) ; Beclometasone; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Acronyms TALC
- 08 Apr 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 28 Oct 2010 Results published in the New England Journal of Medicine.
- 17 Sep 2010 Primary endpoint 'Morning peak expiratory flow rate' has been met.